RESEARCHER PROFILE
Dr Erin Brazel
University of Adelaide
Filmed February 2024
Dr Erin Brazel has a background in molecular and translational microbiology, with a focus on developing new ways of preventing and treating bacterial diseases. Recently Dr Brazel has been awarded a Junior Fellowship by the Passe & Williams Memorial Foundation.
The fellowship enables outstanding individuals to obtain postdoctoral training under the supervision of an experienced clinical or scientific researcher, with the view to establishing a research career in Otolaryngology, Head and Neck Surgery in Australia and/or New Zealand.
The fellowship will support research on bacterial vaccines in a joint GPN Vaccines Ltd and the University of Adelaide project to explore combination vaccines for ear infections using Gamma-PN.
Bacterial ear infections are the most common bacterial disease affecting children. In Australia, episodes range from 1-2.4 million each year, affecting over 600,000 individuals, with 40% of these children experiencing six or more recurrences before the age of eight. Persistent cases can result in hearing loss and learning difficulties, leading to developmental delays and impacts on psychosocial health. Chronic ear infections have also been linked to increased rates of obesity during childhood and Later in life, which may be a result of prolonged antibiotic usage.
With antibiotic resistant superbugs projected to kill 10 million people each year by 2050, new ways of combatting disease are urgently required. A major focus of Dr Brazel’s research is the development of new vaccines to address emerging and existing pathogens that threaten global health and biosecurity. Vaccines are an important tool for reducing disease caused by antimicrobial resistant pathogens, the spread of resistant bacteria, and to reduce antimicrobial use in health and animal care.
Dr Brazel has contributed to the design and preclinical testing of many next generation vaccine candidates, including the current lead candidate (Gamma-PN3). This vaccine is currently being tested in a first-in-human Phase 1 clinical trial (commenced January 2023).
You Might also like
-
Dr Ryan O’Hare Doig
NEIL SACHSE CENTRE FOR SPINAL CORD RESEARCH (SAHMRI)
SOUTH AUSTRALIA
AUSTRALIA -
ROCK-induced early-onset bowel cancer progression
Professor Michael Samuel is a cell biologist whose research interest is in understanding how cancer mechanobiology influences the tumour microenvironment, thereby promoting tumour progression. He is Professor of Matrix Biology at the University of South Australia, Adelaide and heads the Tumour Microenvironment Laboratory at the Centre for Cancer Biology and the Cancer Mechanotherapies Laboratory at the Basil Hetzel Institute for Translational Health Research.
-
Patient reported outcomes in the diagnosis and treatment of lymphoma
Dr. Elizabeth Goodall (BMedSci Hons, MBBS Hons, FRACP, FRCPA) is a PhD student and early career researcher with La Trobe University and the Olivia Newton John Cancer Research Institute (ONJCRI), and Haematologist at Austin Health and Monash Health, Melbourne.
Her specific interest in how patients experience their illness and treatment forms the basis for her research in improving patient outcomes. This research comes at a pivotal time in modern lymphoma management with an ever-increasing number of treatment options available and renewed focus on each patient’s journey.